Takeda appoints new Area Head for India, C.I.S., Middle East, Turkey, and Africa

• Proven leader with more than 20 years of experience in biopharmaceutical industry

Dubai: Takeda Pharmaceutical Company Limited (TSE.:4502/NYSE:TAK) (“Takeda”), announced today the appointment of Dr. Mahender Nayak as Area Head for the Company’s ICMEA (India, C.I.S., Middle East, Turkey, and Africa) Area. In his current capacity, Dr. Nayak will lead the company’s operations from Dubai, United Arab Emirates (U.A.E.), where he will be based.

Dr. Nayak has more than 20 years of performance-driven leadership experience in the biopharmaceutical industry, having worked in multinational and regional companies. Before this role, he oversaw Portfolio Management for Takeda’s Growth and Emerging Markets Business Unit based in Singapore (2018 to 2020). Prior to that, Dr. Nayak was the General Manager of Takeda’s operations in Korea.

Commenting on his new role, Dr. Nayak said, “This is an exciting time to move to a part of the world that is teeming with great opportunities to increase patient access to Takeda’s highly innovative medicines. We aim to do this through our commercial activities and commitments around our approaches to Access to Medicines across rare diseases, oncology, neuroscience, and gastroenterology.”

Across ICMEA, Takeda collaborates with governments and regulators, to ensure that its diverse portfolio of innovative medicines is made available to patients as quickly and safely as possible.

“These countries are open to innovation and partnering with world-leading R&D-led organizations like Takeda. Our diverse talent across the company’s presence in over 82 geographies bring many different experiences, backgrounds, cultures, and perspectives that help drive health innovation and ultimately benefit patients. This can only be done by nurturing and developing the best talents and ultimately becoming an employer of choice”, added Dr. Nayak.

Dr. Nayak started his career as a physician in Bangalore, India and has an MBA in Marketing.  He joined Takeda in 2011 and, since then, grew within the company to hold various senior international and regional roles.

-Ends-

About Takeda Pharmaceuticals

Takeda Pharmaceutical Company Limited (T.S.E.:4502/NYSE: T.A.K.) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (G.I.), Neuroscience, and Rare Diseases. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.

For more information, visit https://www.takeda.com 

Takeda’s Forward-Looking Statements
This press release contains “forward-looking statements.” Forward-looking statements include all statements other than statements of historical fact, including plans, strategies and expectations for the future, statements regarding the expected timing of filings and approvals relating to the transaction, the expected timing of the completion of the transaction, the ability to complete the transaction or to satisfy the various closing conditions, future revenues and profitability from or growth or any assumptions underlying any of the foregoing. Statements made in the future tense, and words such as “anticipate,” “expect,” “project,” “continue,” “believe,” “plan,” “estimate,” “pro forma,” “intend,” “potential,” “target,” “forecast,” “guidance,” “outlook,” “seek,” “assume,” “will,” “may,” “should,” and similar expressions are intended to qualify as forward-looking statements. Forward-looking statements are based on estimates and assumptions made by management that are believed to be reasonable, though they are inherently uncertain and difficult to predict. Investors and security holders are cautioned not to place undue reliance on these forward-looking statements.

Forward-looking statements involve risks and uncertainties that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements. Some of these risks and uncertainties include, but are not limited to: required regulatory approvals for the transaction may not be obtained in a timely manner, if at all; the conditions to closing of the transaction may not be satisfied; competitive pressures and developments; applicable laws and regulations; the success or failure of product development programs; actions of regulatory authorities and the timing thereof; changes in exchange rates; and claims or concerns regarding the safety or efficacy of marketed products or product candidates in development. The forward-looking statements contained in this press release speak only as of the date of this press release, and neither Portal Instruments nor Takeda undertake any obligation to revise or update any forward-looking statements to reflect new information, future events or circumstances after the date of the forward-looking statement. If one or more of these statements is updated or corrected, investors and others should not conclude that additional updates or corrections will be made.

© Press Release 2020